Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The expansion includes a larger technical and service team and increased local procurement
The new facility is expected to generate 500-600 new jobs in the region
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
Subscribe To Our Newsletter & Stay Updated